文献リスト

1）Sugano K. Should we still subcategorize Helicobacter pylori-associated dyspepsia as functional disease? J Neurogastroenterol Motil. 2011; 17: 366-71

2）Miwa H, Ghoshal UC, Gonlachanvit S, et al. Asian consensus report on functional dyspepsia. J Neurogastroenterol Motil. 2012; 18: 150-68

3）van Kerkhoven LA, Laheij RJ, Meineche-Schmidt V, et al. Functional dyspepsia: not all roads seem to lead to rome. J Clin Gastroenterol. 2009; 43: 118-22

4）Tack J, Janssen P. Emerging drugs for functional dyspepsia. Expert Opin Emerg Drugs. 2011; 16: 283-92.

5）Oshima T, Nakajima S, Yokoyama T, et al. The G-protein beta3 subunit 825 TT genotype is associated with epigastric pain syndrome-like dyspepsia. BMC Med Genet. 2010; 11: 13.

6）Toyoshima F, Oshima T, Nakajima S, et al. Serotonin transporter gene polymorphism may be associated with functional dyspepsia in a Japanese population. BMC Med Genet. 2011; 12: 88.

7）Tahara T, Shibata T, Wang F, et al. Genetic polymorphisms of molecules associated with innate immune responses, TRL2 and MBL2 genes in Japanese subjects with functional dyspepsia. J Clin Biochem Nutr. 2010; 47: 217-23

8）Tahara T, Shibata T, Nakamura M, et al. Homozy-gous TRPV1 315C influences the susceptibility to functional dyspepsia. J Clin Gastroenterol. 2010; 44: e1-e7

9）Shimpuku M, Futagami S, Kawagoe T, et al. G-protein β3 subunit 825CC genotype is associated with postprandial distress syndrome with impaired gastric emptying and with the feeling of hunger in Japanese. Neurogastro-enterol Motil. 2011; 23: 1073-80

10）Oshima T, Toyoshima F, Nakajima S, et al. Genetic factors for functional dyspepsia. J Gastroenterol Hepatol. 2011; 26(Supple 3): 83-7

11）Oshima T, Okugawa T, Tomita T, et al. Generation of dyspeptic symptoms by direct acid and water infusion into the stomachs of functional dyspepsia patients and healthy subjects. Aliment Pharmacol Ther. 2012; 35: 175-82

12）Tanimura T, Adachi K, Furuta K, et al. Usefulness of catheterless radiotelemetry pH monitoring system to examine the relationship between duodenal acidity and upper gastrointestinal symptoms. J Gastroenterol Hepatol. 2011; 26: 98-103

13）Futagami S, Shindo T, Kawagoe T, et al. Migration of eosinophils and CCR2-/CD68-double positive cells into the duodenal mucosa of patients with postinfectious functional dyspepsia. Am J Gastroenterol. 2010; 105: 1835-42

14）Li X, Chen H, Lu H, et al. The study on the role of inflammatory cells and mediators in post-infectious functional dyspepsia. Scand J Gastroenterol. 2010; 45: 573-81

15）Kindt S, Tertychnyy A, de Hertogh G, et al. Intestinal immune activation in presumed post-infectious functional dyspepsia. Neurogastro-enterol Motil. 2009; 21: 832-e56

16）Walker MM, Salehian SS, Murray CE, et al. Implications of eosinophilia in the normal duodenal biopsy - an association with allergy and functional dyspepsia. Aliment Pharmacol Ther. 2010; 31: 1229-36

17）Ishii M, Manabe N, Kusunoki H, et al. Real-time evaluation of dyspeptic symptoms and gastric motility induced by duodenal acidification using noninvasive transnasal endoscopy. J Gastro-enterol. 2008; 43: 935-41.

18）Ishihara S, Aziz M, Oshima N, et al. Irritable bowel syndrome and inflammatory bowel disease: infectious gastroenteritis-related disorders ? Clin J Gastroenterol. 2009; 2: 9-16

19）Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009; 136: 1979-88

20）Ford AC, Thabane M, Collins SM, et al. Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. Gastroenterology. 2010; 138: 1727-36

21）Liebregts T, Adam B, Bredack C, et al. Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia. Am J Gastroenterol. 2011; 106: 1089-98

22）Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ. 2000; 321: 659-64

23）Mazzoleni LE, Sander GB, Francesconi CF, et al. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med. 2011; 171: 1929-36

24）Ford AC, Moayyedi P, Jarbol DE, et al. Meta-analysis: Helicobacter pylori‘test and treat compared with empirical acid suppression for managing dyspepsia. Aliment Pharmacol Ther. 2008; 28: 534-44

25）Meineche-Schmidt V, Christensen E, Bytzer P. Randomised clinical trial: identification of responders to short-term treatment with esomeprazole for dyspepsia in primary care - a randomised, placebo-controlled study. Aliment Pharmacol Ther. 2011; 33: 41-9

26）van Zanten SV, Wahlqvist P, Talley NJ, et al. Randomised clinical trial: the burden of illness of uninvestigated dyspepsia before and after treatment with esomeprazole--results from the STARS II study. Aliment Pharmacol Ther. 2011; 34: 714-23

27）Gerson LB, Kahrilas PJ, Fass R. Insights into gastroesophageal reflux disease-associated dyspeptic symptoms. Clin Gastroenterol Hepatol. 2011; 9: 824-33

28）Kinoshita Y, Chiba T; FUTURE Study Group. Characteristics of Japanese patients with chronic gastritis and comparison with functional dyspepsia defined by ROME III criteria: based on the large-scale survey, FUTURE study. Intern Med. 2011; 50: 2269-76

29）Kinoshita Y, Chiba T; FUTURE study group. Therapeutic effects of famotidine on chronic symptomatic gastritis: subgroup analysis from FUTURE study. J Gastroenterol. 2012; 47: 377-86

30）木下芳一，春間　賢，三輪洋人．ディスペプシア症状を有する胃食道逆流症患者を対象としたランソプラゾール投与による自覚症状改善効果の検討（LEGEND study） 日本消化器病学会雑誌. 2011; 108（臨時増刊号）: A477.

31）富永和作，鈴木秀和，楠　裕明．RabeprazoleによるFunctional dyspepsia患者の症状改善効果－プラセボ対照二重盲検比較試験－the CAESAR study. 日本消化器病学会雑誌. 2009; 106（臨時増刊号）: A161

32）富永和作，岩切龍一，古田賢司．機能性ディスペプシアに対するラベプラゾール治療有効性：プラセボ対照多施設共同無作為二重盲検比較試験：the SAMURAI study. 日本消化器病学会雑誌. 2012; 109（臨時増刊号）: A171

33）Wang WH, Huang JQ, Zheng GF, et al. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol. 2007; 5: 178-85

34）Wong WM, Wong BC, Hung WK, et al. Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut. 2002; 51: 502-6

35）van Rensburg C, Berghofer P, Enns R, et al. Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia. Curr Med Res Opin. 2008; 24: 2009-18

36）Hongo M, Harasawa S, Mine T, et al. Large-scale randomized clinical study on functional dys-pepsia treatment with mosapride or teprenone: Japan Mosapride Mega-Study (JMMS). J Gastro-enterol Hepatol. 2012; 27: 12-68

37）Hallerbäck BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther. 2002; 16: 959-67

38）Hiyama T, Yoshihara M, Matsuo K, et al. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J Gastro-enterol Hepatol. 2007; 22: 304-10

39）Hiyama T, Yoshihara M, Matsuo K, et al. Treatment of functional dyspepsia with serotonin agonists: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2007; 22: 1566-70

40）Talley NJ, Tack J, Ptak T, et al. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut. 2008; 57: 740-6

41）Vakil N, Laine L, Talley NJ, et al. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol. 2008; 103: 1906-19

42）Adam B, Liebregts T, Zschau NB, et al. Z-338 Improves meal-induced symptoms in functional dyspepsia: a double-blind, randomized, placebo controlled crossover study. Gastroenterology. 2009; 136: A535

43）Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emp-tying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol & Motil. 2012; in press

44）Tack J, Masclee A, Heading R, et al. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil. 2009; 272-80

45）Matsueda K, Hongo M, Sasaki D, et al. Therapeutic efficacy of novel agent (Z-338) in functional dyspepsia. Gastroenterology. 2005; 128: A467

46）Talley N, Tack J, Kowalski D, et al. A novel ace-tylcholine esterase inhibitor acotiamide hydro-chloride (YM443) in functional dyspepsia: effi-cacy in a randomized, double-blind, placebo-controlled dose ranging trial. Gastroenterology. 2008; 134: A157

47）Matsueda K, Hongo M, Tack J, et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia – 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil. 2010; 22: 618-e173

48）Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2011; doi:10.10.1136/gutjnl-2011-301454

49）Hsu YC, Liou JM, Yang TH, et al. Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups ? J Gastroenterol. 2011; 46: 183-90

50）van Kerkhoven LA, Laheij RJ, Aparicio N, et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2008; 6: 746-52

51）Miwa H, Nagahara A, Tominaga K, et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol. 2009; 104: 2779-87

52）Coffin B, Bortolloti C, Bourgeois O, et al. Efficacy of a simethicone, activated charcoal and mag-nesium oxide combination (Carbosymag®) in functional dyspepsia: results of a general practice-based randomized trial. Clin Res Hepatol Gastroenterol. 2011; 35: 494-9

53）Miller V, Whorwell PJ. Hypnotherapy for func-tional gastrointestinal disorders: a review. Int J Clin Exp Hypn. 2009; 57: 279-92

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp